Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSCs for COVID-19 Pneumonia
NCT04293692Withdrawn
- Sponsor
- Puren Hospital Affiliated to Wuhan University of Science and Technology
- Start
- Feb 2020
- Primary completion
- Feb 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Randomised, double-blind trial of human umbilical cord mesenchymal stem cells in COVID-19 pneumonia (2 arms), sponsored by Puren Hospital Affiliated to Wuhan University of Science and Technology. Primary endpoints: Size of lesion area by chest imaging at Week 8 and Blood oxygen saturation at Week 8. Planned start Feb 2020; status: withdrawn.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04293692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04293692.